A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine‐refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) ‐Targeted Therapy. This evidence concerns the gene KDR and thyroid cancer.